OBJECTIVE—The goal of this study was to examine whether maternal dietary intake of vitamin D, ω-3 fatty acids, and ω-6 fatty acids during pregnancy is associated with the appearance of islet autoimmunity (IA) in offspring.

RESEARCH DESIGN AND METHODS—The Diabetes Autoimmunity Study in the Young (DAISY) is recruiting at birth and following children at increased risk for type 1 diabetes, as determined by HLA-DR genotype or by family history of type 1 diabetes. A total of 233 mothers of newly recruited DAISY subjects were asked to recall their intake of food and nutritional supplements during the third trimester of pregnancy using the Willett food frequency questionnaire. Children were followed for an average of 4 years (range 0.8–7.3 years) for the appearance of insulin, GAD65, and IA-2 autoantibodies. Sixteen children developed at least one autoantibody during this period. Unadjusted and adjusted hazard ratios (HRs) for the development of IA were estimated with survival analysis using a Weibull distribution.

RESULTS—Maternal intake of vitamin D via food was significantly associated with a decreased risk of IA appearance in offspring, independent of HLA genotype, family history of type 1 diabetes, presence of gestational diabetes mellitus, and ethnicity (adjusted HR = 0.37; 95% CI 0.17–0.78). Vitamin D intake via supplements, ω-3 fatty acids, and ω-6 fatty acids intake during pregnancy were not associated with appearance of IA in offspring.

CONCLUSIONS—Our findings suggest that maternal intake of vitamin D through food during pregnancy may have a protective effect on the appearance of IA in offspring.

Type 1 diabetes is a T-cell–mediated autoimmune disease characterized by the destruction of insulin-producing β-cells of the pancreas. The causes of type 1 diabetes are unknown, yet low concordance rates among monozygotic twins (1), a 10% progression rate among those genetically susceptible (2), migratory studies (3), and increasing worldwide incidence rates (4) suggest that genetic factors interact with environmental factors in the development of type 1 diabetes. These environmental factors have not been clearly identified.

Type 1 diabetes is preceded by a preclinical stage termed islet autoimmunity (IA) that signals the beginning of β-cell destruction with the presence of autoantibodies against islet autoantigens. IA appears typically by 2 years of age and sometimes as early as 3 months of age in individuals with type 1 diabetic first-degree relatives (57). Autoantibodies can be persistent for months or years, often predicting clinical diagnosis, or can be transient. Transient autoantibody positivity has not been associated with genetic risk factors (7,8), suggesting that environmental factors may be involved in suppressing persistent β-cell destruction.

Increased expression of proinflammatory cytokines may be associated with the appearance and persistence of IA (9). Vitamin D and the ω-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown to modify the immune response by suppressing proinflammatory cytokines and promoting anti-inflammatory cytokines (1013). The ω-6 fatty acids, specifically arachidonic acid, have been shown to promote the proinflammatory cytokine prostaglandin E2, which may increase progression of IA toward type 1 diabetes in individuals with high genetic risk for type 1 diabetes (14). Animal studies (1518) and epidemiological studies (1921) have observed the protective effect of vitamin D or ω-3 fatty acids on type 1 diabetes risk.

In utero exposures may influence the child’s risk of IA and type 1 diabetes. Evidence for this stems from observations concerning prenatal exposure to congenital rubella (22) and intake of cod liver oil during pregnancy (21). Recent evidence suggests the possibility of autoimmune reactivity against β-cells in utero (23,24), underscoring the importance of studying in utero exposures when investigating potential type 1 diabetes prevention strategies.

Vitamin D, ω-3 fatty acid, and ω-6 fatty acid status in the fetus and newborn child is dependent on maternal intake during pregnancy (2527). Considering the rapid increase in type 1 diabetes incidence among 0–5 year olds (28) and early appearance of IA, maternal intake of certain dietary nutrients during pregnancy may provide sufficient in utero exposure to these nutrients, offering early protection from or promotion of IA in infancy or early childhood.

Previous studies have been limited because they assessed exposures after the appearance of disease, which could lead to bias, and/or they have only examined supplemental exposures as opposed to exposures via foods, which may result in misclassification. Therefore, we examined whether maternal dietary and/or supplemental intakes during pregnancy of vitamin D, ω-3 fatty acids, and ω-6 fatty acids are associated with the appearance of IA in children using dietary intake data that were measured before the appearance of the outcome.

### Study population

Informed consent was obtained from the parents of each study subject at enrollment, and the Colorado Multiple Institutional Review Board approved all study protocols. Subjects were identified through the Diabetes Autoimmunity Study in the Young (DAISY), a birth-cohort recruited from the Denver metropolitan area that investigates the natural history of IA in infants and children at moderate to high risk for developing type 1 diabetes. DAISY children were recruited in two ways. The first was through a screening program of all children born at St. Joseph Hospital in Denver, Colorado, via testing of umbilical cord blood samples for diabetes-susceptibility alleles in the HLA region. Details on screening are available elsewhere (29). Results of HLA typing placed subjects into three risk groups that are determined by the odds of developing type 1 diabetes by the age of 20 years: high 1:16; moderate 1:75 (in non-Hispanic Caucasians) or 1:230 (in Hispanics); or low <1:300. The second method of DAISY recruitment was through identifying children with first-degree type 1 diabetic relatives through the Colorado type 1 diabetes registry, the Barbara Davis Center (Denver, CO), the Children’s Hospital (Denver, CO), or media publicity.

### Collection of maternal diet during pregnancy

Maternal third trimester exposures were assessed via a self-administered Willett Food Frequency Questionnaire (FFQ) sent to mothers at DAISY enrollment ∼2–3 months after delivery. Assessments began in January 1996. Our cohort comprised 233 children whose mother completed an FFQ. The FFQ inquired about the usual intake of food and vitamins over a defined period of time. It listed foods with serving sizes and nine options for frequency of intake ranging from never or less than once per month to six or more serving sizes per day. For vitamin supplements, the FFQ inquired about brand name, constituents, dose, and frequency. The FFQs were sent to the Channing Laboratory at Harvard University for scanning and nutritional data analysis. Nutrient scores were computed by multiplying the frequency of intake by the nutrient content of the item using data from the U.S. Department of Agriculture, food manufacturers, and other published sources. Data on serum concentrations of vitamin D and erythrocyte membrane fatty acids during pregnancy were not available.

Intakes of vitamin D via food and vitamin D via supplements were analyzed separately. Vitamin D intake via food was analyzed as a continuous variable in international units (IU). Vitamin D intake via supplements was dichotomized using a cutoff of 400 IU to distinguish between those above and below the recommended daily consumption of vitamin D. Indicators of ω-3 fatty acid intake were measured through the intake of linolenic acid and a combined intake of EPA and DHA. A dichotomization value of 0.1 g for EPA and DHA intake was chosen based upon recent research that reported daily intake of 0.1 g EPA and DHA reflects an average frequency of fish intake of one to three servings per month (30). In our cohort, we assumed that women acquired EPA and DHA through fish consumption. The ω-6 fatty acid intake was captured through intake of linoleic acid and intake of arachidonic acid. We also calculated the ratio of total ω-6 fatty acid intake to total ω-3 fatty acid intake.

### Descriptive data collection

We examined sociodemographic and pregnancy indicators to determine their association with IA, which were collected with structured questionnaires. Sociodemographic indicators included child’s sex, mother’s age at time of delivery, mother’s educational attainment at time of delivery (≤high school versus >12 years), mother’s income at time of delivery (<$30,000 vs. ≥$30,000), and ethnicity (non-Hispanic Caucasian versus “Other”). The “Other” ethnicity category included Hispanic (18.92%), American Indian (0.90%), Asian (0.90%), African American (2.70%), and biracial (1.35%). Variables relating to pregnancy included child’s birth weight, a preterm or post-term delivery date (yes/no), cesarean delivery (yes/no), breast-feeding duration (<3 months vs. ≥3 months), and development of gestational diabetes mellitus (GDM) (yes/no). We also examined genetic risk factors as indicated by subject’s relation to a type 1 diabetic first-degree relative (yes/no) and subject’s diabetes-susceptibility HLA-DR genotype (HLA-DR3/4, DQ8 versus other genotypes).

### Measurement of autoantibodies and definition of outcome

For the purposes of this study, the definition of IA was positivity for one or more of the three islet autoantibodies on at least one occasion. We excluded positivity due to transplacental transmission of autoantibodies, as indicated by positivity at the 9-month blood draw and negative on all subsequent visits. Children with positive results for any of the antibodies tested were placed on an accelerated blood draw schedule of every 3–6 months for the duration of the study. Of the 16 children who met this definition of IA, 5 have since been diagnosed with type 1 diabetes, 6 were autoantibody positive at last follow-up, and 5 have subsequently tested negative for autoantibodies. We also did some exploratory analysis with a more strict definition of IA, which included only the 11 children who were autoantibody positive on two consecutive visits and still positive (or diabetic) at the last visit.

### Statistical analysis

We used parametric survival analysis (PROC LIFEREG) and specified the Weibull distribution to estimate all univariate and adjusted hazard ratios (HRs) and calculated corresponding approximate 95% CI (33,34). We started accrual of follow-up time from birth. Due to fixed-interval blood draws, the exact timing of IA development was unknown and varied for affected subjects. Thus, the outcome for all affected subjects was interval censored, and the interval was determined by the difference in the age of the affected subject at the first positive visit and their age at the last negative visit. Two subjects were positive at their first blood draw (∼9 months of age) and were left censored. Subjects not considered affected had variable lengths of follow-up and were right censored. There were 11 pairs of siblings (9.4%) in the cohort. One sibling from each of the 11 families was randomly deleted to avoid violating the assumption of independence.

Variables for which we did not have a priori reasons for choosing a categorization value were tested for log linearity of outcome. To test log linearity, we first calculated tertile values for each variable, then modeled the variable as an ordered categorical variable and as separate categories based upon tertile values, and evaluated linearity using the likelihood ratio test (P < 0.20 indicated nonlinearity). For all models, variables meeting the assumption of log linearity were entered as continuous variables, whereas variables violating the assumption of log linearity were entered as tertiles.

Tests for confounding began with a saturated survival model and proceeded in a manual backward stepwise fashion. Variables were retained in the final model if their exclusion would have resulted in a >10% change in the magnitude of the HR for the dietary variable of interest. The SAS V8e statistical software package was used for all analyses.

The average age at last follow-up for the affected and unaffected groups is 4.3 ± 1.9 and 4.0 ± 1.4 years, respectively. Age at first positive IA test was 2.5 ± 1.7 years and ranged from 0.76 to 6.0 years. Univariate analysis revealed a significantly increased hazard of IA associated with mothers having GDM (HR 9.64; 95% CI 2.74–33.97) (Table 1).

Maternal intake of vitamin D through food was associated with a decreased risk of IA in offspring univariately (HR 0.49; 95% CI 0.26–0.94) (Table 2), and after adjustment for HLA genotype, family history of type 1 diabetes, presence of GDM, and ethnicity (adjusted HR 0.37; 0.17–0.78) (Table 3). This HR represents a 63% decrease in risk associated with an SD increase in dietary vitamin D intake during pregnancy (vitamin D SD 155.6 IU). The remaining exposure variables were nonsignificant univariately and remained so after adjustment for relation to a type 1 diabetic first-degree relative, HLA-DR genotype, and GDM (data not shown). Exploratory analysis of persistent IA/diabetes suggested a protective effect of vitamin D via food, although the effect was lower in magnitude and nonsignificant compared with the less restrictive IA model (Table 3).

Our findings suggest that maternal intake of vitamin D through food during pregnancy may have a protective effect on the appearance of IA in offspring. While other studies have examined related questions (21), our study is the first to examine in utero dietary exposures using a cohort design in which exposure is assessed and then the cohort is followed for the outcome. This design is free of recall bias, a weakness commonly attached to study designs in which exposures are assessed after the appearance of disease. Also, the DAISY cohort was created by selectively screening for subjects at increased genetic risk of type 1 diabetes. Although this results in a cohort that is not representative of the general population, the cohort is otherwise free of exposure-dependent selection bias. In addition, our study design accounted for the level of exposure through dose and frequency assessments, aspects not accounted for in past epidemiological reports (19,21).

FFQs are appropriate for assessing diet in pregnant women (3538), although there is a tendency for overestimation of intake (39). While the period of recall was relatively short, we recognize that nondifferential misclassification of dietary exposure was also possible because each mother assessed her third trimester intake at ∼2–3 months after delivery. However, overestimation and nondifferential misclassification are more likely to bias the measure of association toward the null rather than away from the null and therefore would not explain our results regarding dietary vitamin D. In fact, given the potential for nondifferential misclassification, our analyses may actually be underestimating the effect of maternal intake. Only a biomarker of vitamin D could better confirm vitamin D exposure, as it would account for vitamin D acquired through diet as well as sunlight, the latter of which we were unable to account for in this study. However, exposure to sunlight is a readily available source of vitamin D in Colorado and would likely not differ among affected and unaffected groups. In the DAISY children, plasma 25, hydroxyvitamin D levels were significantly associated with vitamin D intake as measured by the Willett FFQ, suggesting that the questionnaire was producing a valid measure of vitamin D intake (40).

The previous epidemiological studies that observed the protective effect of vitamin D (1921) used type 1 diabetes as the outcome. However, considering that IA is the initial signal of β-cell destruction, that it often appears early in life, and that it can last for years before clinical diagnosis of type 1 diabetes, identifying exposures associated with the appearance of IA, regardless of its persistence, offers an opportunity for type 1 diabetes prevention at its most primitive stage. Our outcome definition includes transient IA subjects. While transient IA more weakly predicts progression toward type 1 diabetes compared with persistent IA, it is our observation that 13% of the DAISY subjects who lost their antibodies gained them back at a later date (M.R., J.M.N., unpublished data). Interestingly, 11.7% (n = 2) of the 17 DAISY subjects followed from birth who have developed type 1 diabetes were classified with transient IA at some time before type 1 diabetes diagnosis (M.R., J.M.N., unpublished data). The number of subjects who developed at least one autoantibody was relatively small, and CIs for significant results under this outcome were wide, implying that further studies are needed to verify this association.

Because high-risk genetic factors and multiple appearances of islet autoantibodies on more than one occasion significantly influence progression toward type 1 diabetes (8), we explored an outcome defined with persistent IA (i.e., positive for an autoantibody on two consecutive occasions and still positive or type 1 diabetes at last visit). However, restricting our outcome reduced our already small affected group by >30%. The trend of protection with vitamin D via food remained, but statistical significance was not observed with this or any other exposure. This is likely due to the small number of persistent IA subjects, resulting in weak power to detect a significant difference between affected and unaffected groups.

We did not find a significant association between combined intake of EPA and DHA and risk of IA in offspring. The power to detect a significant difference between the affected and unaffected groups with respect to this exposure was limited. We had only 12% power to detect a significant result with respect to a combined intake of EPA and DHA given that 91% of the unaffected group reported intake of <0.10 g EPA and DHA daily. One concern regarding the EPA and DHA levels in our cohort was that pregnant women might consume too little fish to provide a valid estimate of EPA and DHA, considering women are advised against fish consumption during pregnancy due to increased risk of fetal mercury exposure. Indeed, the levels of EPA and DHA intake are slightly lower in our cohort than levels reported by other cohorts (30) for women aged 34–59 years using the same FFQ (median daily intake, 0.14 and 0.17 g, respectively). Therefore, additional studies in populations consuming more fish may be necessary to further address fish intake during pregnancy and IA in offspring.

Interestingly, we did not find an association between vitamin D intake via supplements and IA, which is similar to observations in another epidemiological study (21). The reasoning is not clear as to why we observed an association with vitamin D intake via food and not via supplements. The inconsistency could be due to residual confounding unaccounted for in the analysis in that women who take less than the recommended amount of vitamin D may be different from those who take the recommended amount or more. Alternatively, the inconsistency might be explained by differences in power due to differences in the distribution of the two variables, in that we had 48% power to obtain a significant result given that 90% of the unaffected group received at least 400 IU of vitamin D supplementation. However, these explanations are likely too simplistic considering the nonsignificant HR for the vitamin D supplement variable was in the opposite direction of the vitamin D intake via food variable. Perhaps in utero, the bioavailability of vitamin D may be greater when acquired through food, even if the food is simply fortified with vitamin D, as opposed to manufactured multivitamin supplements taken alone. Alternatively, an unidentified nutrient that is available in foods containing vitamin D or a combination of vitamin D and this nutrient could be responsible for the association between vitamin D via food and IA in offspring. To design effective prevention strategies, studies are needed to determine whether the protective factor is vitamin D itself, a nutrient that accompanies vitamin D in foods, or an interaction between vitamin D and another nutrient.

Table 1—

Demographic and pregnancy characteristics and risk of IA in offspring

n 16 206
Age at last follow-up (years)* 4.3 ± 1.9 4.0 ± 1.4 NA NA
Child’s sex (% male) 7 (43.7) 101 (49.0) 0.87 (0.32–2.33) 0.779
Child’s ethnicity (% non-Hispanic Caucasian) 15 (93.7) 152 (73.8) 5.29 (0.7–40.06) 0.133
Maternal age at delivery (years) 31.3 ± 6.0 29.7 ± 5.8 1.26 (0.8–1.96) 0.331
Maternal education at delivery (% ≤12 years) 4 (25.0) 48 (23.3) 1.09 (0.35–3.39) 0.878
Income at delivery (% <$30,000/year)§ 4 (26.7) 48 (23.8) 1.04 (0.33–3.28) 0.942 Birth weight (g)§ 3,122.9 ± 564.9 3,286.4 ± 527.7 0.74 (0.47–1.18) 0.238 Pre- or post-term delivery§ 2 (13.3) 69 (33.7) 0.31 (0.07–1.37) 0.148 Cesarean delivery 1 (6.2) 43 (20.9) 0.27 (0.04–2.04) 0.226 Breast-fed <3 months§ 6 (37.5) 66 (32.3) 1.3 (0.47–3.56) 0.619 GDM 3 (18.8) 3 (1.5) 9.64 (2.74–33.97) 0.006 First-degree type 1 diabetic relative 6 (37.5) 62 (30.1) 1.71 (0.62–4.75) 0.302 HLA-DR3/4, DQ8 genotype 14 (87.5) 129 (62.6) 3.17 (0.72–14.01) 0.166 CharacteristicAffectedUnaffectedUnadjusted HR (95% CI)Wald χ2P n 16 206 Age at last follow-up (years)* 4.3 ± 1.9 4.0 ± 1.4 NA NA Child’s sex (% male) 7 (43.7) 101 (49.0) 0.87 (0.32–2.33) 0.779 Child’s ethnicity (% non-Hispanic Caucasian) 15 (93.7) 152 (73.8) 5.29 (0.7–40.06) 0.133 Maternal age at delivery (years) 31.3 ± 6.0 29.7 ± 5.8 1.26 (0.8–1.96) 0.331 Maternal education at delivery (% ≤12 years) 4 (25.0) 48 (23.3) 1.09 (0.35–3.39) 0.878 Income at delivery (% <$30,000/year)§ 4 (26.7) 48 (23.8) 1.04 (0.33–3.28) 0.942
Birth weight (g)§ 3,122.9 ± 564.9 3,286.4 ± 527.7 0.74 (0.47–1.18) 0.238
Pre- or post-term delivery§ 2 (13.3) 69 (33.7) 0.31 (0.07–1.37) 0.148
Cesarean delivery 1 (6.2) 43 (20.9) 0.27 (0.04–2.04) 0.226
Breast-fed <3 months§ 6 (37.5) 66 (32.3) 1.3 (0.47–3.56) 0.619
GDM 3 (18.8) 3 (1.5) 9.64 (2.74–33.97) 0.006
First-degree type 1 diabetic relative 6 (37.5) 62 (30.1) 1.71 (0.62–4.75) 0.302
HLA-DR3/4, DQ8 genotype 14 (87.5) 129 (62.6) 3.17 (0.72–14.01) 0.166

Data are means ± SD or n (%) unless otherwise indicated.

*

For affected, average age at first positive test for IA is 2.5 ± 1.7 years;

outcome determined by difference in age of affected subject at first positive visit and age at last negative visit;

HR associated with incremental values: maternal age = 5 years, birth weight = 500 g;

§

missing observations include income: one in the affected group (6.2%) and four (1.9%) in the unaffected group, birth weight: one from the unaffected group (0.5%), pre- or post-term delivery: one in each affected (6.2%) and unaffected group (0.5%), and breast-feeding duration: two missing observations from unaffected group (1.0%).

Table 2—

Maternal dietary exposures during pregnancy and risk of IA in offspring

Parameters (mean daily intake)AffectedUnaffectedUnadjusted HR (95% CI)Wald χ2P
n 16 206
Vitamin D intake via food (IU) 167.6 252.3 0.49 (0.26–0.94)* 0.059
Vitamin D intake via supplements (IU)
≥400 13 (81.3) 116 (56.3) 3.09 (0.88–10.83) 0.107
EPA and DHA (ω-3 fatty acids) (g)
≥0.10 9 (56.3) 137 (66.5) 0.64 (0.24–1.71) 0.380
Linolenic acid (ω-3 fatty acid) (g) 1.4 1.3 1.16 (0.75–1.80)* 0.503
Arachidonic acid (ω-6 fatty acid) (g) 0.13 0.14 0.88 (0.5–1.56)* 0.672
Linoleic acid (ω-6 fatty acid) (g)
<7.92 4 (25.0) 71 (34.5) 1.0 (referent)
7.92–11.78 8 (50.0) 66 (32.0) 2.01 (0.55–7.37) 0.274
>11.78 4 (25.0) 69 (33.5) 1.04 (0.26–4.16) 0.955
Ratio of ω-6 total:ω-3 total 7.9 7.8 1.13 (0.70–1.83)* 0.624
Caloric intake (kcal)
<1,718.88 5 (31.2) 68 (33.0) 1.0 (referent)
1,718.88–2,491.04 9 (56.2) 67 (32.5) 1.61 (0.54–4.82) 0.405
>2,491.04 2 (12.5) 71 (34.5) 0.37 (0.07–1.93) 0.258
Parameters (mean daily intake)AffectedUnaffectedUnadjusted HR (95% CI)Wald χ2P
n 16 206
Vitamin D intake via food (IU) 167.6 252.3 0.49 (0.26–0.94)* 0.059
Vitamin D intake via supplements (IU)
≥400 13 (81.3) 116 (56.3) 3.09 (0.88–10.83) 0.107
EPA and DHA (ω-3 fatty acids) (g)
≥0.10 9 (56.3) 137 (66.5) 0.64 (0.24–1.71) 0.380
Linolenic acid (ω-3 fatty acid) (g) 1.4 1.3 1.16 (0.75–1.80)* 0.503
Arachidonic acid (ω-6 fatty acid) (g) 0.13 0.14 0.88 (0.5–1.56)* 0.672
Linoleic acid (ω-6 fatty acid) (g)
<7.92 4 (25.0) 71 (34.5) 1.0 (referent)
7.92–11.78 8 (50.0) 66 (32.0) 2.01 (0.55–7.37) 0.274
>11.78 4 (25.0) 69 (33.5) 1.04 (0.26–4.16) 0.955
Ratio of ω-6 total:ω-3 total 7.9 7.8 1.13 (0.70–1.83)* 0.624
Caloric intake (kcal)
<1,718.88 5 (31.2) 68 (33.0) 1.0 (referent)
1,718.88–2,491.04 9 (56.2) 67 (32.5) 1.61 (0.54–4.82) 0.405
>2,491.04 2 (12.5) 71 (34.5) 0.37 (0.07–1.93) 0.258

Data are n (%) unless otherwise indicated.

*

HR represent risk for an SD difference in intake: SD vitamin D = 155.6 IU; SD linolenic acid = 0.69 g; SD arachidonic acid = 0.08 g; SD ratio ω-6 total to ω-3 total = 2.00;

categorized as tertiles because variable did not meet the assumption of log linearity.

Table 3—

Multivariate survival analysis examining maternal vitamin D intake via food during pregnancy and risk of IA and persistent IA

Risk factors*IA adjusted HR (95% CI)Wald χ2PPersistent IA adjusted HR (95% CI)Wald χ2P
n 16  11
Vitamin D intake via food (IU) 0.37 (0.17–0.78) 0.020 0.58 (0.27–1.28) 0.205
First-degree type 1 diabetic relative 5.15 (1.45–18.28) 0.021 6.74 (1.62–28.03) 0.031
HLA-DR 3/4, DQ8 genotype 9.79 (1.69–56.83) 0.029 9.14 (1.50–55.85) 0.054
GDM 7.78 (1.83–33.03) 0.011 2.05 (0.22–19.02) 0.528
Child’s ethnicity (% non-Hispanic Caucasian) 6.97 (0.88–55.46) 0.088 Not calculable NA
Risk factors*IA adjusted HR (95% CI)Wald χ2PPersistent IA adjusted HR (95% CI)Wald χ2P
n 16  11
Vitamin D intake via food (IU) 0.37 (0.17–0.78) 0.020 0.58 (0.27–1.28) 0.205
First-degree type 1 diabetic relative 5.15 (1.45–18.28) 0.021 6.74 (1.62–28.03) 0.031
HLA-DR 3/4, DQ8 genotype 9.79 (1.69–56.83) 0.029 9.14 (1.50–55.85) 0.054
GDM 7.78 (1.83–33.03) 0.011 2.05 (0.22–19.02) 0.528
Child’s ethnicity (% non-Hispanic Caucasian) 6.97 (0.88–55.46) 0.088 Not calculable NA
*

All variables entered into model simultaneously;

HR represents risk for a 155.6 IU SD difference in intake;

all affected were non-Hispanic Caucasian.

This work was supported by the National Institutes of Health Grants R01-DK-49654 and R01-DK-32493 and the Diabetes Endocrinology Research Center Clinical Investigation & Biometrics Core NIH P30 DK57516.

1.
Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K, Reunanen A, Eriksson J, Stengard J, Kesaniemi YA: Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland.
Diabetologia
35
:
1060
–1067,
1992
2.
Couper JJ: Environmental triggers of type 1 diabetes.
J Paediatr Child Health
37
:
218
–220,
2001
3.
Bodansky HJ, Staines A, Stephenson C, Haigh D, Cartwright R: Evidence for an environmental effect in the etiology of insulin dependent diabetes in a transmigratory population.
BMJ
304
:
1020
–1022,
1992
4.
Onkamo P, Vaananen S, Karvonen M, Tuomilehto J: Worldwide increase in incidence of type I diabetes: the analysis of the data on published incidence trends.
Diabetologia
42
:
1395
–1403,
1999
5.
Kimpimaki T, Kupila A, Hamalainen AM, Kukko M, Kulmala P, Savola K, Simell T, Keskinen P, Ilonen J, Simell O, Knip M: The first signs of β-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish Type 1 Diabetes Prediction and Prevention Study.
J Clin Endocrinol Metab
86
:
4782
–4788,
2001
6.
Ziegler AG, Hillebrand B, Rabl W, Mayrhofer M, Hummel M, Mollenhauer U, Vordemann J, Lenz A, Standl E: On the appearance of islet associated autoimmunity in offspring of diabetic mothers: a prospective study from birth.
Diabetologia
36
:
402
–408,
1993
7.
Colman PG, Steele C, Couper JJ, Beresford SJ, Powell T, Kewming K, Pollard A, Gellert S, Tait B, Honeyman M, Harrison LC: Islet autoimmunity in infants with a type I diabetic relative is common but is frequently restricted to one autoantibody.
Diabetologia
43
:
203
–209,
2000
8.
Yu J, Yu L, Bugawan TL, Erlich HA, Barriga K, Hoffman M, Rewers M, Eisenbarth GS: Transient antiislet autoantibodies: infrequent occurrence and lack of association with “genetic” risk factors.
J Clin Endocrinol Metab
85
:
2421
–2428,
2000
9.
Kukreja A, Maclaren NK: Autoimmunity and diabetes.
J Clin Endocrinol Metab
84
:
4371
–4378,
1999
10.
Saggese G, Federico G, Balestri M, Toniolo A: Calcitriol inhibits the PHA-induced production of IL-2 and IFN-γ and the proliferation of human peripheral blood leukocytes while enhancing the surface expression of HLA class II molecules.
J Endocrinol Invest
12
:
329
–335,
1989
11.
Deluca HF, Cantorna MT: Vitamin D: its role and uses in immunology.
FASEB J
15
:
2579
–2585,
2001
12.
Calder PC: More good news about fish oil.
Nutrition
17
:
158
–160,
2001
13.
Calder PC: Polyunsaturated fatty acids, inflammation, and immunity.
Lipids
36
:
1007
–1024,
2001
14.
Litherland SA, Xie XT, Hutson AD, Wasserfall C, Whittaker DS, She JX, Hofig A, Dennis MA, Fuller K, Cook R, Schatz D, Moldawer LL, Clare-Salzler MJ: Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus.
J Clin Invest
104
:
515
–523,
1999
15.
Mathieu C, Laureys J, Sobis H, Vandeputte M, Waer M, Bouillon R: 1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice.
Diabetes
41
:
1491
–1495,
1992
16.
Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R: Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3.
Diabetologia
37
:
552
–558,
1994
17.
Suresh Y, Das UN: Protective action of arachidonic acid against alloxan-induced cytotoxicity and diabetes mellitus.
Prostaglandins Leukot Essent Fatty Acids
64
:
37
–52,
2001
18.
Krishna Mohan I, Das UN: Prevention of chemically induced diabetes mellitus in experimental animals by polyunsaturated fatty acids.
Nutrition
17
:
126
–151,
2001
19.
EURODIAB Substudy 2 Study Group: Vitamin D supplement in early childhood and risk for type I (insulin-dependent) diabetes mellitus.
Diabetologia
42
:
51
–54,
1999
20.
Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM: Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study.
Lancet
358
:
1500
–1503,
2001
21.
Stene LC, Ulriksen J, Magnus P, Joner G: Use of cod liver oil during pregnancy associated with lower risk of type I diabetes in the offspring.
Diabetologia
43
:
1093
–1098,
2000
22.
Menser MA, Forrest JM, Bransby RD: Rubella infection and diabetes mellitus.
Lancet
1
:
57
–60,
1978
23.
Greeley SA, Katsumata M, Yu L, Eisenbarth GS, Moore DJ, Goodarzi H, Barker CF, Naji A, Noorchashm H: Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice.
Nat Med
8
:
399
–402,
2002
24.
Lindberg B, Ivarsson SA, Landin-Olsson M, Sundkvist G, Svanberg L, Lernmark A: Islet autoantibodies in cord blood from children who developed type I (insulin-dependent) diabetes mellitus before 15 years of age.
Diabetologia
42
:
181
–187,
1999
25.
Zeghoud F, Vervel C, Guillozo H, Walrant-Debray O, Boutignon H, Garabedian M: Subclinical vitamin D deficiency in neonates: definition and response to vitamin D supplements.
Am J Clin Nutr
65
:
771
–778,
1997
26.
Delvin EE, Salle BL, Glorieux FH, Adeleine P, David LS: Vitamin D supplementation during pregnancy: effect on neonatal calcium homeostasis.
J Pediatr
109
:
328
–334,
1986
27.
Connor WE, Lowensohn R, Hatcher L: Increased docosahexaenoic acid levels in human newborn infants by administration of sardines and fish oil during pregnancy.
Lipids
31
:
S183
–S187,
1996
28.
EURODIAB ACE Study Group: Variation and trends in incidence of childhood diabetes in Europe.
Lancet
355
:
873
–876,
2000
29.
Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M, McDuffie RS Jr, Hamman RF, Klingensmith G, Eisenbarth GS, Erlich HA: Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY).
Diabetologia
39
:
807
–812,
1996
30.
Iso H, Rexrode KM, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Hennekens CH, Willett WC: Intake of fish and omega-3 fatty acids and risk of stroke in women.
JAMA
285
:
304
–312,
2001
31.
Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, Eisenbarth GS: Early expression of anti-insulin autoantibodies of man and the NOD mouse: evidence for early determination of subsequent diabetes.
Proc Natl Acad Sci U S A
97
:
1701
–1706,
2000
32.
Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C, Chase P, Klingensmith G, Erlich H, Norris J, Eisenbarth GS: Antiislet autoantibodies usually develop sequentially rather than simultaneously.
J Clin Endocrinol Metab
81
:
4264
–4267,
1996
33.
Allison PD:
Survival Analysis Using the SAS System: A Practical Guide
. Cary, NC, SAS Institute,
1995
34.
Collett D:
Modeling Survival Data in Medical Research
. London, Chapman and Hall,
1994
35.
Suitor CJ, Gardner J, Willett WC: A comparison of food frequency and diet recall methods in studies of nutrient intake of low-income pregnant women.
J Am Diet Assoc
89
:
1786
–1794,
1989
36.
Greeley S, Storbakken L, Magel R: Use of a modified food frequency questionnaire during pregnancy.
J Am Coll Nutr
11
:
728
–734,
1992
37.
Robinson S, Godfrey K, Osmond C, Cox V, Barker D: Evaluation of a food frequency questionnaire used to assess nutrient intakes in pregnant women.
Eur J Clin Nutr
50
:
302
–308,
1996
38.
Brown JE, Buzzard IM, Jacobs DR Jr, Hannan PJ, Kushi LH, Barosso GM, Schmid LA: A food frequency questionnaire can detect pregnancy-related changes in diet.
J Am Diet Assoc
96
:
262
–266,
1996
39.
Erkkola M, Karppinen M, Javanainen J, Rasanen L, Knip M, Virtanen SM: Validity and reproducibility of a food frequency questionnaire for pregnant Finnish women.
Am J Epidemiol
154
:
466
–476,
2001
40.
Brady HL, Ross C, Rewers M, Sokol R, Norris JM: Plasma vitamin D status and development of β-cell autoimmunity in young children (Abstract).
Diabetes
51(Suppl. 2)
:
A220
,
2002

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.